This invention relates to liquid phase separation and/or concentration of particles, cells, or particles in solution. In particular, it relates to separation or concentration from flowing liquids. It provides a means to simply and rapidly extract target objects from complex mixtures. Such devices are useful in systems for, e.g., medical therapy (similar to dialysis), but also for detection, purification, and synthesis. A specific embodiment is in the magnetic separation of pathogens from infected blood.
Chemical and biological separation and concentration has historically included methods such as solid-phase extraction, filtration chromatography, flow cytometry and others. Known methods of magnetic separation in biological fields include aggregation in batches, capture on magnetized surfaces, and particle deflection (or “steering”) in single-channel devices. Typically, the particle of interest is chemically bound to magnetic microparticles or nanoparticles.
Existing methods are typically batch processes rather than continuous free-flow processes. This limits their usefulness in in-line systems. Moreover, existing methods typically operate at the macroscale, where diffusion distances require slower flow speeds, resulting in limited throughput. This problem is compounded in single-channel devices. The present invention improves on known methods and apparatuses for magnetic separation of particles from a fluid by providing a continuous, free-flow, higher throughput separation.
The present invention includes systems, methods, and other means for separating molecules, cells, or particles from liquids, including aqueous solutions. The present invention may utilize a flow cell with a plurality of microfluidic separation channels. The present invention may utilize a magnetic housing to provide a magnetic field gradient across each of the microfluidic separation channels to separate particles, cells, or molecules from an aqueous solution. In one aspect, the present invention relates to a flow cell for separating or concentrating particles.
In some embodiments of the present invention, the flow cell has an upstream end and a downstream end. The flow cell includes a plurality of separation channels. The plurality of separation channels, in one embodiment, are array perpendicularly with respect to both fluid flow through the channels and the predominant direction of the magnetic field gradient applied across the channels. At the upstream end, the flow cell includes two input ports. One input port introduces into the channel a fluid stream containing a target particle, cell, or molecule, and potentially other particles, cells, or molecules. The other input port introduces into the flow channel another fluid stream. The channel includes two output ports. One output port receives most of the first fluid stream. The second output port receives most of the second fluid stream and most of the target particles from the first stream.
In one embodiment, the flow cell can be a removable insert that can be placed into a magnetic housing. In one embodiment, the flow cell can be disposable. Because the flow cell contains no magnetic parts, it can be manufactured simply and at low cost.
In another aspect, the invention relates to a magnetic housing for applying a magnetic field gradient across each of the separation channels of the flow cell. The magnetic housing includes a stage for positioning a flow cell. The magnetic housing also includes at least one plate for applying a magnetic field gradient across each of the separation channels in the flow cell. The magnetic housing also includes a magnetic source. The magnetic source is the source of the magnetic field gradient created between the stage and the plate.
In some embodiments, the stage can be positioned for inserting or removing a flow cell. Such an embodiment can be used in conjunction with the removable flow cell as described herein. Such an embodiment can also be used in conjunction with a removable disposable flow cell as described herein. In some embodiments, the surface of the stage is flat. In other embodiments, the surface of the stage is shaped to change the shape of the magnetic field gradient. The stage can be made of any permeable metal, but is preferably made of high-permeability metal.
In some embodiments, the surface of the plate has a shape selected to concentrate the magnetic field gradient across each of the separation channels. For example the surface of the plate may includes rectangular, rounded, or prismatic protrusions spaced to align with respective separation channels.
In some embodiments, the magnetic source is a permanent magnet. In other embodiments, the magnetic source is an electromagnet.
In some embodiments, the magnetic housing can be shaped like the letter “C”. In other embodiments, the magnetic housing can be composed of two plates in parallel. In either embodiment, the magnetic field gradient may be generated by a permanent magnet or an electromagnet.
In another aspect, the invention relates to a method for separating or concentrating particles. The method includes flowing the first fluid containing target particles into the flow cell, flowing the second fluid into the flow cell such that the first and second fluids are in laminar flow in the separation channels, applying the magnetic field gradient with appropriate polarity and strength to cause target particles to diffuse from the first fluid into the second fluid, combining the first fluid streams from each of the separation channels into a first output stream, and combining the second fluid streams from each of the separation channels into a second output stream.
The foregoing discussion will be understood more readily from the following detailed description of the invention with reference to the following drawings.
Plate 106 is aligned with flow cell 102 such that the surface of plate 106 is positioned appropriately relative to the separation channels (not visible in this diagram) of flow cell 102. In order to properly align plate 106 and flow cell 102, a “tongue-and-groove” technique can be used, wherein tongue 108 of plate 106 is aligned with groove 110 of flow cell 102 to ensure that the parts are properly positioned relative to each other.
In one embodiment, magnetic housing 104 can be a permanent magnet. The strength of the magnetic field gradient across flow cell 102 may be adjusted by increasing or decreasing the proximity of plate 106 to flow cell 102. Variable shim 112 can be used to adjust the “air gap” between plate 106 and flow cell 102.
In other embodiments, such as the embodiment depicted in
The operation of separation channels 212, 214, and 216 is explained with reference to separation channel 212. Sample fluid stream 222 is shown at the top of separation channel 212. Buffer fluid stream 224 is shown at the bottom of separation channel 212. Interface 238 between the sample fluid stream 222 and buffer fluid stream 224 may have a sigmoidal shape due to transverse fluid-mechanical interactions at interface 238 caused by bringing the two fluid streams 222 and 224 into laminar flow at an angle, as described later with regard to
Target particle 230 can be any type of particle. For example, target particle 230 can be any of a molecule, cell, spore, protein, virus, bacteria, or other particle.
Separation channels 212, 214, and 216 can be about 200 to 300 μm wide, 50 to 200 μm tall, and 1 to 10 cm long. For example, separation channels 212, 214, and 216 may be 250 μm wide×100 μm high, and spaced on a pitch of 500 μm. With those dimensions, a flow rate of 3 ml/min throughput can be achieved in a device area of 10×10 cm. Flow rate can be increased by using a flow cell with more separation channels. Although flow cell 202 is depicted with only three separation channels, a flow cell of the present invention could incorporate many more separation channels, for example 200 separation channels.
Layers 232 and 234 of flow cell 202 form the top and bottom of flow channels 212, 214, and 216, respectively. The distance between the top of separation channels 212, 214, and 216, and the top of flow cell 202 is determined, in party, by the thickness of layer 232. The distance between the bottom of separation channels 212, 214, and 216, and the bottom of the flow cell 202 is determined, in party, by the thickness of layer 234. Because the magnetic field gradient is a function of distance between the separation channels and plate 208, and between the separation channels, and stage 210, the thickness of layers 232 and 234 may be altered in some embodiments in order to adjust magnetic field gradient strength across separation channels 212, 214, and 216. The channels can be brought within 300 μm of the magnets, achieving a highly parallel array with field strengths and gradients comparable to those demonstrated in a single channel. For example, in some embodiments, the thickness of layers 232 and 234 may be between 200 μm and 300 μm, such as 250 μm. The magnetic field gradient strength may also be adjusted in other ways. In some embodiments, air gap 236 between flow cell 202 and plate 208 and stage 210 may be altered in order to adjust magnetic field gradient strength across separation channels 212, 214, and 216.
In some embodiments, the walls of separation channels 212, 214, and 216 may be treated to improve bio-compatibility. For example, a flow cell fabricated using Polydimethylsiloxane (PDMS) may be plasma treated to improve the bio-compatibility of the PDMS.
In some embodiments, the walls of separation channels 212, 214, 216 may be coated with a bio-compatible coating in order to reduce surface interactions between the walls of the separation channels and the sample fluid stream or any target particles therein. For example, the walls of separation channels 212, 214, and 216 may be coated with Parylene.
Flow cell 400 also includes area 420 over the channels of separation channels 402, 404, 406, and 408. Area 420 of flow cell 400 can be recessed such that the channels of separation channels 402, 404, 406, and 408 may be brought into closer proximity with a plate of a magnetic housing.
The inlets 602 and 604 are positioned to introduce two fluid streams into the separation channel 606 in laminar flow. The sample inlet 602 introduces sample fluid stream 612 which includes target particles. The buffer inlet 604 introduces buffer fluid stream 614.
The width and depth of the flow channel 606 are selected to allow the fluid streams from inlets 602 and 604 to be in laminar flow through the separation channel 606. The width of flow channel 606 can be between 0.1 mm and 1 mm, for example 0.5 mm wide. The height of flow channel 606 can be between 50 μm and 500 μm, for example 100 μm tall. The length of separation channel 606 is selected to be sufficiently long to allow target particles to have sufficient time to diffuse from one wall 618 of the separation channel across the interface 620 of fluid streams 612 and 614. For example, in one embodiment, the channel is about 2 cm long, though shorter or longer separation channels may also be suitable.
A magnetic housing, discussed above in relation to
Preferably, sample fluid stream 612 includes target particles bound to magnetic or paramagnetic nanoparticles or microparticles, (e.g., paramagnetic beads coupled to antibodies selected to bind to the target particles) to enhance the magnetic susceptibility of the target particles. In some embodiments, bio-functionalized magnetic nanoparticles or microparticles are bound to, or adsorbed by the target particles prior to being flowed through device 600.
At the downstream end of separation channel 606 are sample outlet 608 and buffer outlet 610. Sample outlet 608 collects most of sample fluid stream 612. Buffer outlet 610 collects most of buffer fluid stream 614, as well as target particles, such as target particle 622, which have been moved across interface 620 of fluid streams 612 and 614.
In
In
In
In
In
In
In
In
Magnetic housing 1100 includes alignment pins 1118, 1120, and 1122 for aligning plate 1102 and back plate 1104. Magnetic housing 1100 includes adjustment screw 1124 for adjusting the distance between plate 1102 and back plate 1104. The strength of the magnetic field gradient across the flow cell may be decreased by increasing the distance between the plate 1102 and back plate 1104, or may be increased by decreasing the distance between plate 1102 and back plate 1104.
More specifically, a sample fluid containing particles, cells, or molecules is flowed into a flow cell comprising a plurality of separation channels. A buffer fluid, for collecting the target particles, is flowed into the plurality of separation channels in the flow cell. These streams are flowed at flow rates that maintain laminar flow within the separation channel.
As the fluid streams flow through the separation channel, they flow through a magnetic field gradient applied transverse to the direction of pressure-driven flow in the separation channel. The magnetic field gradient exerts a force on magnetically-susceptible particles, causing them to move in the direction of the buffer fluid stream. The magnetic field gradient strength must be sufficient to cause target particles to move into the buffer fluid stream. At the downstream end of the separation channel, the sample fluid stream is collected at a sample outlet. At the downstream end of the separation channel, the buffer fluid stream is collected at a buffer outlet. The sample fluid stream collected at the outlet has a lower concentration of target particles than it did at the inlet to the separation channel because target particles have migrated to the buffer fluid stream.
If the magnetic susceptibility of a target particle is insufficient to achieve desired rates of separation, or non-target particles may have approximately the same magnetic susceptibility as the target particle, a target particle may be made more responsive to the magnetic field gradient by binding it to a magnetic nanoparticle or microparticle. In such an embodiment, step 1202 may be preceded by mixing the sample fluid with functionalized magnetic nanoparticles or microparticles. The sample fluid, such as blood, is passed repeatedly through a microfluidic mixer, as is commonly known in the art, at a relatively slow rate (˜1 ml/min) in order to promote optimal bead-pathogen binding. After being allowed to bind optimally to the particles in the mixer, a process which takes approximately 5 to 10 minutes, the sample fluid is allowed to pass through the flow cell where the sample fluid is cleared of most or all magnetic beads and bound pathogens before the sample fluid exits the flow cell.
Flow cell 1324 is depicted from the top in the X-Y plane, and in cross-section in the X-Z plane at locations D, E, and F. Flow cell 1324 has a first inlet 1326 and a second inlet 1328. Without a barrier layer to separate inlets 1326 and 1328 as they merge, the fluid stream flowing through first inlet 1326 comes into contact with the fluid stream flowing through second inlet 1328 before the respective directions of their flow are aligned, as depicted in cross-section 1334. In cross-section 1334, first inlet 1326 overlaps partially with second inlet 1328, and the fluid streams from the respective inlets come into contact with each other. As first inlet 1326 and second inlet 1328 merge to form the separation channel, the two fluids move in the X-direction with respect to each other, introducing a lateral physical shear between the two fluid streams. In such an embodiment, fluid interface 1340 has a sigmoidal shape, as described above with reference to
The invention may be embodied in other specific forms without departing form the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative, rather than limiting of the invention.
This application claims the benefit of U.S. Provisional Application Ser. No. 60/925,355, filed Apr. 19, 2007, the entire contents of which are incorporated herein by reference
Number | Name | Date | Kind |
---|---|---|---|
1583051 | Kennedy | May 1926 | A |
2608390 | Philippe | Aug 1952 | A |
3127738 | Hasbrouck et al. | Apr 1964 | A |
3128794 | Donald et al. | Apr 1964 | A |
3342378 | Mezoff et al. | Sep 1967 | A |
3421739 | Alberts et al. | Jan 1969 | A |
3470912 | Bydal | Oct 1969 | A |
3506244 | Strang | Apr 1970 | A |
3507301 | Larson | Apr 1970 | A |
3510240 | Rhinehart | May 1970 | A |
3847773 | Snyder | Nov 1974 | A |
3852013 | Upmeier | Dec 1974 | A |
3963221 | Yi | Jun 1976 | A |
4214610 | James et al. | Jul 1980 | A |
4222671 | Gilmore | Sep 1980 | A |
4285602 | Hagerty et al. | Aug 1981 | A |
4426344 | Dinter et al. | Jan 1984 | A |
4465582 | Richman | Aug 1984 | A |
4473300 | Goins | Sep 1984 | A |
4518260 | Goins | May 1985 | A |
4553849 | Goins | Nov 1985 | A |
4948481 | Mullner et al. | Aug 1990 | A |
4983038 | Ohki et al. | Jan 1991 | A |
5094788 | Schrenk et al. | Mar 1992 | A |
5180480 | Manz | Jan 1993 | A |
5185071 | Serwer et al. | Feb 1993 | A |
5250188 | Bruening et al. | Oct 1993 | A |
5269995 | Ramanathan et al. | Dec 1993 | A |
5275706 | Weber et al. | Jan 1994 | A |
5518311 | Althaus et al. | May 1996 | A |
5531831 | Sweeney et al. | Jul 1996 | A |
5620714 | Veen | Apr 1997 | A |
5765373 | Bittle et al. | Jun 1998 | A |
5780067 | Herrington, Jr. | Jul 1998 | A |
5803600 | Schubert et al. | Sep 1998 | A |
5816045 | Blocker et al. | Oct 1998 | A |
5824204 | Jerman | Oct 1998 | A |
5826981 | Fowler et al. | Oct 1998 | A |
5904424 | Schwesinger et al. | May 1999 | A |
5932100 | Yager et al. | Aug 1999 | A |
6082891 | Schubert et al. | Jul 2000 | A |
6136171 | Frazier et al. | Oct 2000 | A |
6136272 | Weigl et al. | Oct 2000 | A |
6143152 | Simpson et al. | Nov 2000 | A |
6190034 | Nielsen et al. | Feb 2001 | B1 |
6221677 | Wu et al. | Apr 2001 | B1 |
6225497 | Becker et al. | May 2001 | B1 |
6264900 | Schubert et al. | Jul 2001 | B1 |
6299657 | Schubert et al. | Oct 2001 | B1 |
6321998 | Schubert et al. | Nov 2001 | B1 |
6328868 | Weber et al. | Dec 2001 | B1 |
6387707 | Seul et al. | May 2002 | B1 |
6432630 | Blankenstein | Aug 2002 | B1 |
6454945 | Weigl et al. | Sep 2002 | B1 |
6467503 | Schlesch et al. | Oct 2002 | B2 |
6479734 | Iba et al. | Nov 2002 | B2 |
6623860 | Hu et al. | Sep 2003 | B2 |
6676835 | O'Connor et al. | Jan 2004 | B2 |
6692627 | Russell et al. | Feb 2004 | B1 |
6695147 | Yager et al. | Feb 2004 | B1 |
6705357 | Jeon et al. | Mar 2004 | B2 |
6802640 | Schubert et al. | Oct 2004 | B2 |
6845787 | Karp et al. | Jan 2005 | B2 |
6851846 | Fujii et al. | Feb 2005 | B2 |
6877892 | Karp | Apr 2005 | B2 |
6890093 | Karp et al. | May 2005 | B2 |
6905324 | Cloeren | Jun 2005 | B2 |
6923907 | Hobbs et al. | Aug 2005 | B2 |
6935772 | Karp et al. | Aug 2005 | B2 |
6958245 | Seul et al. | Oct 2005 | B2 |
6981522 | O'Connor et al. | Jan 2006 | B2 |
7005050 | Burns et al. | Feb 2006 | B2 |
7033473 | Gascoyne et al. | Apr 2006 | B2 |
7056746 | Seul et al. | Jun 2006 | B2 |
7077906 | Colombo et al. | Jul 2006 | B2 |
7100636 | King | Sep 2006 | B2 |
7135144 | Christel et al. | Nov 2006 | B2 |
7138269 | Blankenstein | Nov 2006 | B2 |
7258774 | Chou et al. | Aug 2007 | B2 |
7261812 | Karp et al. | Aug 2007 | B1 |
7316503 | Mathys et al. | Jan 2008 | B2 |
7472794 | Oakey et al. | Jan 2009 | B2 |
7487799 | Wobben | Feb 2009 | B2 |
7520661 | Lawson | Apr 2009 | B1 |
7632405 | Siddiqi | Dec 2009 | B2 |
7699767 | Mueth et al. | Apr 2010 | B2 |
20020045738 | Singh et al. | Apr 2002 | A1 |
20020057627 | Schubert et al. | May 2002 | A1 |
20020187503 | Harrold et al. | Dec 2002 | A1 |
20030057092 | Chien et al. | Mar 2003 | A1 |
20040092033 | Gustafson et al. | May 2004 | A1 |
20040182707 | Jardemark et al. | Sep 2004 | A1 |
20040256230 | Yager et al. | Dec 2004 | A1 |
20040257907 | Xu et al. | Dec 2004 | A1 |
20050061669 | Woudenberg et al. | Mar 2005 | A1 |
20050178701 | Roth et al. | Aug 2005 | A1 |
20080067068 | Li | Mar 2008 | A1 |
20080237044 | Fiering et al. | Oct 2008 | A1 |
20090044619 | Fiering et al. | Feb 2009 | A1 |
20090078614 | Varghese et al. | Mar 2009 | A1 |
20090086572 | Miyoshi et al. | Apr 2009 | A1 |
Number | Date | Country |
---|---|---|
3624626 | Jan 1988 | DE |
3926466 | Feb 1991 | DE |
19748481 | May 1999 | DE |
0 434 556 | Jun 1991 | EP |
1 742 057 | Jan 2007 | EP |
WO-9626782 | Sep 1996 | WO |
WO-0187458 | Nov 2001 | WO |
WO-2009023507 | Feb 2009 | WO |
Number | Date | Country | |
---|---|---|---|
20090078614 A1 | Mar 2009 | US |
Number | Date | Country | |
---|---|---|---|
60925355 | Apr 2007 | US |